Tech sell-off resumes, counterbalancing bond yield relief; Moderna surges 124% on melanoma vaccine trial results
Tech stocks, particularly semiconductors like Intel, AMD, and Broadcom, faced renewed selling pressure in early trading. This occurred despite falling bond yields, which buoyed the Dow and S&P 500 after the US Treasury Department supported buybacks of long-dated securities. Meanwhile, Moderna shares soared 124% following positive Phase 3 trial results for its melanoma vaccine developed with Merck, driving strength in the healthcare sector. Basic Materials also led the morning, boosted by a surge in gold futures and gold miner stocks.
No AI analysis yet. Tap the "AI Analysis" button above to generate one now.
Disclaimer: This content reflects the author's personal views only and does not constitute investment advice.
24H Trending
-
1
Oasys (OAS) Project Analysis: The Intersection of Gaming Chains and On-Chain Perpetual Contracts
-
2
Wallstreetcn Analysis: U.S. September non-farm payrolls surprisingly increased by only 29,000, yet the 10-year U.S. Treasury yield still rebounded over 10 basis points to 5.30%, as the market worries about sustained high interest rates.
-
3
Two Iranian Nationals Charged in UK Over Alleged Plot Targeting Jewish Community
-
4
Global Virtual Currency Wallet Types and the Current State of Cryptocurrency Trading Platforms in Mainland China
-
5
AMLT Token Analysis and Market Status
-
6
GoldKash (XGK) Token Analysis: Market Status and Investment Risk Assessment
-
7
HAN Token Analysis: What is HanChain? How to Trade and Acquire It?
-
8
Ping An Bank Becomes First Listed Chinese Lender to Adopt AI Rules; Analysts Expect More Banks to Follow
-
9
Nasdaq, NYSE Arca, and two other major exchanges will add a night trading session, ushering in a 23-hour trading day for US stocks starting December 6.
-
10
BAI Token Analysis: An Overview of a Crypto Asset with Multiple Identities
Markets Today
Recommended Reading








